

# Gerard J Criner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787574/publications.pdf>

Version: 2024-02-01

187  
papers

15,141  
citations

41627

51  
h-index

22488

117  
g-index

191  
all docs

191  
docs citations

191  
times ranked

14708  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of Using Daily Home High-Flow Nasal Therapy in COPD Patients Following a Recent COPD Hospitalization. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2022, 9, 4-14.	0.5	2
2	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	2.5	21
3	Reconsidering the Utility of Race-Specific Lung Function Prediction Equations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 819-829.	2.5	63
4	Efficacy and safety of virtual bronchoscopic navigation with fused fluoroscopy and vessel mapping for access of pulmonary lesions. <i>Respirology</i> , 2022, 27, 357-365.	1.3	16
5	Anti-Granulocyte Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1290-1299.	2.5	19
6	Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2022, , .	0.5	1
7	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 97.	1.4	7
8	Changes in Lung Perfusion in Patients Treated with Percutaneous Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
9	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	0
10	Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 838-845.	2.5	12
11	Meta-analysis and Systematic Review of Bronchoscopic Lung Volume Reduction Through Endobronchial Valves in Severe Emphysema. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2022, 29, 224-237.	0.8	7
12	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 24-36.	2.5	417
13	Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 585-591.e2.	0.9	29
14	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 211-220.	2.5	55
15	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 987-997.	2.5	38
16	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 957-968.	2.5	71
17	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 414-423.	2.5	119
18	Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium+olodaterol. <i>Current Medical Research and Opinion</i> , 2021, 37, 275-284.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research, 2021, 7, 00663-2020.	1.1	7
20	Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 219-229.	0.5	0
21	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 326-335.	0.5	0
22	Venoarterial Extracorporeal Membrane Oxygenation in Massive Pulmonary Embolism-Related Cardiac Arrest: A Systematic Review*. Critical Care Medicine, 2021, 49, 760-769.	0.4	30
23	Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. Annals of the American Thoracic Society, 2021, 18, 1822-1831.	1.5	5
24	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. Respiratory Research, 2021, 22, 126.	1.4	14
25	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society, 2021, 18, 788-798.	1.5	19
26	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2021, 325, 1841.	3.8	43
27	Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update. Respiration, 2021, 100, 969-978.	1.2	20
28	Expression of SARS-CoV-2 Entry Factors in Human Alveolar Type II Cells in Aging and Emphysema. Biomedicines, 2021, 9, 779.	1.4	3
29	Bronchoscopic Lung Volume Reduction with Zephyr Valves for Severe Emphysema. Respiration, 2021, 100, 1-3.	1.2	0
30	Device profile of the Zephyr endobronchial valve in heterogenous emphysema: overview of its safety and efficacy. Expert Review of Medical Devices, 2021, 18, 823-832.	1.4	2
31	HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk. JCI Insight, 2021, 6, .	2.3	3
32	Use of a Digital Chronic Obstructive Pulmonary Disease Respiratory Tracker in a Primary Care Setting: A Feasibility Study. Pulmonary Therapy, 2021, 7, 533-547.	1.1	5
33	Authors'™ Responses to Peer Reviews of "Utility of the ROX Index in Predicting Intubation for Patients With COVID-19-Related Hypoxemic Respiratory Failure Receiving High-Flow Nasal Therapy: Retrospective Cohort Study". Jmirx Med, 2021, 2, e31892.	0.2	0
34	Utility of the ROX Index in Predicting Intubation for Patients With COVID-19-Related Hypoxemic Respiratory Failure Receiving High-Flow Nasal Therapy: Retrospective Cohort Study. Jmirx Med, 2021, 2, e29062.	0.2	9
35	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	2.5	121
36	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 536-545.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Role of Imaging in Bronchoscopic Lung Volume Reduction Using Endobronchial Valve. Journal of Thoracic Imaging, 2021, 36, 131-141.	0.8	5
38	Lung proteomic biomarkers associated with chronic obstructive pulmonary disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1119-L1130.	1.3	14
39	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease. Respiratory Research, 2021, 22, 316.	1.4	6
40	Reply to Jain <i>et al.</i> : Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System: Still a Great Need to "EMPROVE". American Journal of Respiratory and Critical Care Medicine, 2020, 201, 391-392.	2.5	1
41	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respiratory Medicine, the, 2020, 8, 158-170.	5.2	69
42	Interventional Bronchoscopic Therapies for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 547-557.	0.8	4
43	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. Scientific Reports, 2020, 10, 10562.	1.6	14
44	The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD. Journal of Clinical Medicine, 2020, 9, 3832.	1.0	6
45	Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respiratory Research, 2020, 7, e000650.	1.2	64
46	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. Chest, 2020, 157, 1391-1392.	0.4	1
47	COVID-19 in lung transplant recipients. Transplant Infectious Disease, 2020, 22, e13364.	0.7	36
48	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	3.8	104
49	Measuring disease activity in COPD: is clinically important deterioration the answer?. Respiratory Research, 2020, 21, 134.	1.4	18
50	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research, 2020, 21, 139.	1.4	9
51	Rheumatologists and Pulmonologists at Temple University Weather the COVID-19 Storm Together. Journal of Rheumatology, 2020, 47, 1723.1-1723.	1.0	4
52	The Oral-Lung Axis: The Impact of Oral Health on Lung Health. Respiratory Care, 2020, 65, 1211-1220.	0.8	43
53	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	2.5	151
54	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	2.5	28

#	ARTICLE	IF	CITATIONS
55	Interventional Bronchoscopy. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 29-50.	2.5	52
56	Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD. Chest, 2020, 157, 856-865.	0.4	35
57	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. Chest, 2020, 158, 529-538.	0.4	8
58	Mobilization and Preparation of a Large Urban Academic Center during the COVID-19 Pandemic. Annals of the American Thoracic Society, 2020, 17, 922-925.	1.5	13
59	Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. Annals of the American Thoracic Society, 2020, 17, 829-838.	1.5	17
60	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight, 2020, 5, .	2.3	37
61	Microarray analysis identifies defects in regenerative and immune response pathways in COPD airway basal cells. ERJ Open Research, 2020, 6, 00656-2020.	1.1	5
62	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2020, 7, 370-381.	0.5	5
63	Bronchoscopic lung volume reduction: status quo. Annals of Translational Medicine, 2020, 8, 1469-1469.	0.7	6
64	Tolerability and Safety of High-Flow Nasal Therapy in Patients Hospitalized with an Exacerbation of COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2020, 7, 362-369.	0.5	1
65	Mitochondrial dysfunction in human primary alveolar type II cells in emphysema. EBioMedicine, 2019, 46, 305-316.	2.7	46
66	The relationship between DJ-1 and S100A8 in human primary alveolar type II cells in emphysema. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L791-L804.	1.3	8
67	The role of DJ-1 in human primary alveolar type II cell injury induced by e-cigarette aerosol. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L475-L485.	1.3	23
68	Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1354-1362.	2.5	97
69	The effect of cysteine oxidation on DJ-1 cytoprotective function in human alveolar type II cells. Cell Death and Disease, 2019, 10, 638.	2.7	27
70	Impaired non-homologous end joining in human primary alveolar type II cells in emphysema. Scientific Reports, 2019, 9, 920.	1.6	13
71	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	13.9	180
72	Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema. Chest, 2019, 155, 928-937.	0.4	29

#	ARTICLE	IF	CITATIONS
73	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation “ Update 2019. <i>Respiration</i> , 2019, 97, 548-557.	1.2	72
74	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019, 53, 1900164.	3.1	1,223
75	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 721-731.	2.5	40
76	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 487-496.	5.2	119
77	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 575-581.	2.5	110
78	Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. <i>Chest</i> , 2019, 155, 908-917.	0.4	18
79	Characteristics at the time of oxygen initiation associated with its adherence: Findings from the COPD Long-term Oxygen Treatment Trial. <i>Respiratory Medicine</i> , 2019, 149, 52-58.	1.3	7
80	miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation. <i>ERJ Open Research</i> , 2019, 5, 00138-2019.	1.1	35
81	Sonographic Evaluation of Diaphragmatic Dysfunction. <i>Journal of Thoracic Imaging</i> , 2019, 34, W131-W140.	0.8	9
82	Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 125-132.	1.0	5
83	Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema. <i>Biomarkers</i> , 2019, 24, 232-239.	0.9	8
84	Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. <i>Respiratory Medicine</i> , 2019, 147, 37-43.	1.3	21
85	Effects of Roflumilast on Rehospitalization and Mortality in Patients. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2019, 6, 74-85.	0.5	2
86	Effect of Lung Volume Reduction Surgery on Respiratory Muscle Strength in Advanced Emphysema. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2019, 6, 40-50.	0.5	1
87	The cytoprotective role of DJ-1 and p45 NFE2 against human primary alveolar type II cell injury and emphysema. <i>Scientific Reports</i> , 2018, 8, 3555.	1.6	15
88	Submassive Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 588-598.	2.5	50
89	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <i>New England Journal of Medicine</i> , 2018, 378, 1671-1680.	13.9	823
90	Human Lung DNA Methylation Quantitative Trait Loci Colocalize with Chronic Obstructive Pulmonary Disease Genome-Wide Association Loci. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1275-1284.	2.5	56

#	ARTICLE	IF	CITATIONS
91	Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). <i>Sleep</i> , 2018, 41, .	0.6	33
92	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. <i>Annals of the American Thoracic Society</i> , 2018, 15, 89-101.	1.5	8
93	Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. <i>Biomedical Chromatography</i> , 2018, 32, e4102.	0.8	26
94	Patient Preferences for Endobronchial Valve Treatment of Severe Emphysema. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2018, 6, 51-63.	0.5	2
95	Preventing clinically important deterioration with single-inhaler triple therapy in COPD. <i>ERJ Open Research</i> , 2018, 4, 00047-2018.	1.1	22
96	Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease. <i>Journal of Molecular Medicine</i> , 2018, 96, 1375-1385.	1.7	17
97	A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1151-1164.	2.5	253
98	Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1296-1303.	1.5	8
99	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. <i>Chest</i> , 2018, 154, 266-273.	0.4	18
100	Activation and polarization of circulating monocytes in severe chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2018, 18, 101.	0.8	37
101	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1000-1011.	2.5	111
102	Ensemble genomic analysis in human lung tissue identifies novel genes for chronic obstructive pulmonary disease. <i>Human Genomics</i> , 2018, 12, 1.	1.4	35
103	Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2018, 5, 177-184.	0.5	36
104	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 324-330.	2.5	221
105	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. <i>Respirology</i> , 2017, 22, 575-601.	1.3	299
106	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 557-582.	2.5	2,393
107	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 636-642.	1.5	30
108	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. <i>Archivos De Bronconeumología</i> , 2017, 53, 128-149.	0.4	312

#	ARTICLE	IF	CITATIONS
109	Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1280-1287.	1.5	60
110	Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. <i>Scientific Reports</i> , 2017, 7, 44232.	1.6	76
111	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2017. <i>Respiration</i> , 2017, 94, 380-388.	1.2	55
112	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1613-1629.	13.9	397
113	Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. <i>Postgraduate Medicine</i> , 2017, 129, 725-733.	0.9	3
114	Azithromycin and risk of COPD exacerbations in patients with and without <i>Helicobacter pylori</i> . <i>Respiratory Research</i> , 2017, 18, 109.	1.4	3
115	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 464-472.	2.5	59
116	Daily Peak Expiratory Flow Rate and Disease Instability in Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2016, 3, 398-405.	0.5	15
117	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1016-1025.	1.5	36
118	Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2178.	3.8	208
119	Effect of Emphysema Severity on the Apnea-Hypopnea Index in Smokers with Obstructive Sleep Apnea. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1129-1135.	1.5	57
120	Non-pharmacological treatments for COPD. <i>Respirology</i> , 2016, 21, 791-809.	1.3	29
121	DNA methylation profiling in human lung tissue identifies genes associated with COPD. <i>Epigenetics</i> , 2016, 11, 730-739.	1.3	73
122	Could digital health applications improve the health of COPD patients?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 377-378.	1.0	2
123	β <sub>2</sub> -Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (β <sub>2</sub> LOCK) Tj ETQq1 1 0,784314 rgBT /Ov	0.8	29
124	Analysis of Asthma- Chronic Obstructive Pulmonary Disease Overlap Syndrome Defined on the Basis of Bronchodilator Response and Degree of Emphysema. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1483-1489.	1.5	44
125	The Role of Lobe Selection on FEV <sub>1</sub> Response in Endobronchial Valve Therapy. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 477-482.	0.7	5
126	Multiplanar MDCT measurement of esophageal hiatus surface area: association with hiatal hernia and GERD. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 2465-2472.	1.3	35



#	ARTICLE	IF	CITATIONS
127	A Telemedicine-Based Intervention Reduces the Frequency and Severity of COPD Exacerbation Symptoms: A Randomized, Controlled Trial. <i>Telemedicine Journal and E-Health</i> , 2016, 22, 114-122.	1.6	42
128	Use of a SmartPhone/Tablet-Based Bidirectional Telemedicine Disease Management Program Facilitates Early Detection and Treatment of COPD Exacerbation Symptoms. <i>Telemedicine Journal and E-Health</i> , 2016, 22, 395-399.	1.6	12
129	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , 2016, 12, e1006011.	1.5	88
130	Hospitalizations and ED Visits in COPD: A Collision of Socioeconomic Realities with Chronic Comorbid Medical Illnesses. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2016, 3, 509-511.	0.5	0
131	Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2015, 15, 111.	0.8	12
132	Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 389.	0.9	23
133	Chronic Bronchitis and Current Smoking Are Associated with More Goblet Cells in Moderate to Severe COPD and Smokers without Airflow Obstruction. <i>PLoS ONE</i> , 2015, 10, e0116108.	1.1	48
134	The Role of Noninvasive Ventilation in the Management and Mitigation of Exacerbations and Hospital Admissions/Readmissions for the Patient With Moderate to Severe COPD (Multimedia Activity). <i>Chest</i> , 2015, 147, 1704-1705.	0.4	8
135	Prevention of Acute Exacerbations of COPD. <i>Chest</i> , 2015, 147, 894-942.	0.4	230
136	Executive Summary. <i>Chest</i> , 2015, 147, 883-893.	0.4	51
137	Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection. <i>Immunity</i> , 2015, 42, 566-579.	6.6	263
138	Heart Failure and Respiratory Hospitalizations Are Reduced in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With the Use of an Implantable Pulmonary Artery Pressure Monitoring Device. <i>Journal of Cardiac Failure</i> , 2015, 21, 240-249.	0.7	50
139	Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 592-608.	0.8	43
140	A randomised trial of lung sealant <i>versus</i> medical therapy for advanced emphysema. <i>European Respiratory Journal</i> , 2015, 46, 651-662.	3.1	105
141	Air Current Applied to the Face Improves Exercise Performance in Patients with COPD. <i>Lung</i> , 2015, 193, 725-731.	1.4	26
142	High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) for Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients - See more at: <a href="http://journal.copdfoundation.org/#sthash.CDAuozRw.dpuf">http://journal.copdfoundation.org/#sthash.CDAuozRw.dpuf</a> . <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2015, 2, 313-320.	0.5	8
143	Is Methicillin-Resistant Staphylococcus Aureus Colonization Associated with Worse Outcomes in COPD Hospitalizations?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2015, 2, 252-258.	0.5	3
144	Risk Factors for Venous Thromboembolism in Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 1, 239-249.	0.5	28

#	ARTICLE	IF	CITATIONS
145	Examining ABO Compatible Donors in Double Lung Transplants During the Era of Lung Allocation Score. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1167-1174.	0.7	14
146	Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema - Potential Mechanisms, Treatment Algorithm, and Case Examples. <i>Respiration</i> , 2014, 87, 513-521.	1.2	92
147	The clinical impact of non-obstructive chronic bronchitis in current and former smokers. <i>Respiratory Medicine</i> , 2014, 108, 491-499.	1.3	65
148	Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. <i>Respiratory Medicine</i> , 2014, 108, 722-728.	1.3	52
149	Radiological correlates and clinical implications of the paradoxical lung function response to $\hat{I}^{22}$ agonists: an observational study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 911-918.	5.2	21
150	Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. <i>European Respiratory Journal</i> , 2014, 43, 387-396.	3.1	73
151	Reduced dynamic hyperinflation after LVRS is associated with improved exercise tolerance. <i>Respiratory Medicine</i> , 2014, 108, 1491-1497.	1.3	4
152	Single-lung transplantation with ABO-compatible donors results in excellent outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 822-828.	0.3	14
153	Clinical characteristics and prediction of pulmonary hypertension in severe emphysema. <i>Respiratory Medicine</i> , 2014, 108, 482-490.	1.3	32
154	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. <i>Chest</i> , 2014, 146, 941-950.	0.4	71
155	Risk of Death by Comorbidity Prompting Rehospitalization Following the Initial COPD Hospitalization. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 17-22.	0.5	4
156	Editorial: Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 91-93.	0.5	1
157	Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 1, 221-228.	0.5	1
158	Chronic Bronchitis and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 228-237.	2.5	334
159	Preventing Acute Exacerbations and Hospital Admissions in COPD. <i>Chest</i> , 2013, 143, 1444-1454.	0.4	52
160	Ambulatory Home Oxygen: What Is the Evidence for Benefit, and Who Does It Help?. <i>Respiratory Care</i> , 2013, 58, 48-64.	0.8	29
161	Optimizing the 6-Min Walk Test as a Measure of Exercise Capacity in COPD. <i>Chest</i> , 2012, 142, 1545-1552.	0.4	27
162	Alternatives to Lung Transplantation: Lung Volume Reduction for COPD. <i>Clinics in Chest Medicine</i> , 2011, 32, 379-397.	0.8	18

#	ARTICLE	IF	CITATIONS
163	Racial Differences in Quality of Life in Patients With COPD. <i>Chest</i> , 2011, 140, 1169-1176.	0.4	61
164	Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. <i>Annals of Internal Medicine</i> , 2011, 155, 179.	2.0	896
165	The National Emphysema Treatment Trial (NETT). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 763-770.	2.5	49
166	The National Emphysema Treatment Trial (NETT). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 881-893.	2.5	180
167	The Chronic Bronchitic Phenotype of COPD. <i>Chest</i> , 2011, 140, 626-633.	0.4	280
168	Outcomes of COPD Exacerbations Treated with Corticosteroids, Antibiotics, or Both. <i>ISRN Pulmonology</i> , 2011, 2011, 1-6.	0.3	1
169	Lung Volume Reduction Surgery and Lung Volume Reduction in Advanced Emphysema: Who and Why?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 348-364.	0.8	10
170	Advanced COPD: Pathogenesis, Evaluation, and Treatment. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 255-255.	0.8	0
171	A Randomized Study of Endobronchial Valves for Advanced Emphysema. <i>New England Journal of Medicine</i> , 2010, 363, 1233-1244.	13.9	704
172	Biologic Lung Volume Reduction in Advanced Upper Lobe Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 791-798.	2.5	103
173	Treatment of Persistent Pulmonary Air Leaks Using Endobronchial Valves. <i>Chest</i> , 2009, 136, 355-360.	0.4	208
174	CT Metrics of Airway Disease and Emphysema in Severe COPD. <i>Chest</i> , 2009, 136, 396-404.	0.4	87
175	National Emphysema Treatment Trial: The Major Outcomes of Lung Volume Reduction Surgery in Severe Emphysema. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 393-405.	3.5	51
176	A Clinician's Guide to the Use of Lung Volume Reduction Surgery. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 461-467.	3.5	17
177	Efficacy of Tiotropium Inhalation Powder in African-American Patients with Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 35-41.	0.7	22
178	Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 171-175.	3.5	2
179	Sex Differences in Severe Pulmonary Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 243-252.	2.5	301
180	Effect of Lung Volume Reduction Surgery on Resting Pulmonary Hemodynamics in Severe Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 253-260.	2.5	81

#	ARTICLE	IF	CITATIONS
181	Effect of Bilateral Lung Volume Reduction Surgery on FEV <sub>1</sub> Decline in Severe Emphysema. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 203-208.	0.7	7
182	Long-term ventilation introduction and perspectives. Respiratory Care Clinics of North America, 2002, 8, 345-353.	0.5	8
183	Care of the patient requiring invasive mechanical ventilation. Respiratory Care Clinics of North America, 2002, 8, 575-592.	0.5	13
184	Dose-Response Characteristics of Nebulized Albuterol in the Treatment of Acutely Ill, Hospitalized Asthmatics. Journal of Asthma, 1999, 36, 539-546.	0.9	8
185	Effect of Lung Volume Reduction Surgery on Diaphragm Strength. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1578-1585.	2.5	88
186	Surgery for severe COPD. Postgraduate Medicine, 1998, 103, 179-202.	0.9	4
187	Lung volume reduction surgery for the treatment of advanced emphysema. , 0, , 69-85.		0